Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis

Executive Summary

Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.

Advertisement

Related Content

Alnylam Plans Lumasiran Phase III As Market Landscape Gets Competitive
Biogen Moves Into Neuropsychiatry With Pfizer AMPA Receptor Modulator
Zydus Partners Medicure To Launch First Branded Drug In US
Evotec Leverages Infectious Diseases Space With Sanofi R&D Deal
Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab
Erenumab Moves Ahead In Treatment-Refractory Migraine in Novartis/Amgen LIBERTY Study
FDA's NDA And BLA Approvals: Xepi, Admelog, Ixifi
Santen Readies India Expansion Via Centaur Alliance
Scrip's Rough Guide To IDO
Akcea Faces Tricky Risk/Benefit Scenario In Orphan Disease FCS

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel